Portal de Periódicos da CAPES

Lesional dendritic cells in patients with chronic atopic dermatitis and psoriasis exhibit parallel ability to activate T-cell subsets

2011; Elsevier BV; Volume: 128; Issue: 3 Linguagem: Inglês

10.1016/j.jaci.2011.05.016

1097-6825

Hideki Fujita, Avner Shemer, Mayte Suárez‐Fariñas, Leanne M. Johnson-Huang, Suzanne J. Tintle, Irma Cardinale, Judilyn Fuentes‐Duculan, Inna Novitskaya, John A. Carucci, James G. Krueger, Emma Guttman‐Yassky,

T-cell and B-cell Immunology

BackgroundAtopic dermatitis (AD) and psoriasis represent polar immune diseases. AD is a TH2/TH22-dominant disease, whereas psoriasis is considered a TH1/TH17 disease. Local immune deviation is suggested to be regulated by dendritic cell (DC)–induced T-cell polarization and recruitment of specific T-cell subsets by chemokines. Although the role of chemokines is well documented, the actual contribution of DCs to activate polar T-cell subsets in human subjects is still a matter of speculation.ObjectiveWe sought to elucidate the significance of each cutaneous DC subset in disease-specific T-cell immune deviation.MethodsWe performed a comprehensive analysis of major cutaneous resident (Langerhans cells and blood dendritic cell antigen 1–positive dermal DCs) and inflammatory (inflammatory dendritic epidermal cells and blood dendritic cell antigen 1–negative dermal DCs) DC subsets directly isolated from the lesional skin of patients with AD and those with psoriasis.ResultsThe ability of each DC subset to expand TH1, TH2, TH17, and TH22 subsets was similar between the 2 diseases, despite the association of both with accumulation of resident and inflammatory DCs. We also confirmed differential upregulation of chemokine expression in patients with AD (CCL17, CCL18, and CCL22) and psoriasis (CXCL1, IL-8, and CCL20). The expression of CCL17 and CCL22 was higher in Langerhans cells from patients with AD than from patients with psoriasis, whereas the opposite was observed for CXCL9 and CXCL10.ConclusionOur results suggest that DC polarity does not directly drive differential T-cell subset responses. Alternatively, disease-specific chemokines might recruit specific memory T-cell subsets into the skin, which in turn might be activated and expanded by DCs at the site of inflammation, maintaining differential immune polarity in these diseases. Atopic dermatitis (AD) and psoriasis represent polar immune diseases. AD is a TH2/TH22-dominant disease, whereas psoriasis is considered a TH1/TH17 disease. Local immune deviation is suggested to be regulated by dendritic cell (DC)–induced T-cell polarization and recruitment of specific T-cell subsets by chemokines. Although the role of chemokines is well documented, the actual contribution of DCs to activate polar T-cell subsets in human subjects is still a matter of speculation. We sought to elucidate the significance of each cutaneous DC subset in disease-specific T-cell immune deviation. We performed a comprehensive analysis of major cutaneous resident (Langerhans cells and blood dendritic cell antigen 1–positive dermal DCs) and inflammatory (inflammatory dendritic epidermal cells and blood dendritic cell antigen 1–negative dermal DCs) DC subsets directly isolated from the lesional skin of patients with AD and those with psoriasis. The ability of each DC subset to expand TH1, TH2, TH17, and TH22 subsets was similar between the 2 diseases, despite the association of both with accumulation of resident and inflammatory DCs. We also confirmed differential upregulation of chemokine expression in patients with AD (CCL17, CCL18, and CCL22) and psoriasis (CXCL1, IL-8, and CCL20). The expression of CCL17 and CCL22 was higher in Langerhans cells from patients with AD than from patients with psoriasis, whereas the opposite was observed for CXCL9 and CXCL10. Our results suggest that DC polarity does not directly drive differential T-cell subset responses. Alternatively, disease-specific chemokines might recruit specific memory T-cell subsets into the skin, which in turn might be activated and expanded by DCs at the site of inflammation, maintaining differential immune polarity in these diseases.